Adaptive RNA Delivery Systems for Specialized Immunization Needs

Publication ID: 24-11857562_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive RNA Delivery Systems for Specialized Immunization Needs,” Published Technical Disclosure No. 24-11857562_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857562_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,562.

Summary of the Inventive Concept

This inventive concept adapts RNA delivery systems for immunization to cater to specific, narrow markets or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions.

Background and Problem Solved

The original patent disclosed a composition for non-viral delivery of RNA for immunization, but it had limitations in terms of stability and efficacy in diverse environments. The new inventive concept addresses these limitations by introducing specialized RNA delivery systems tailored to specific operational environments.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for immunizing animals in extreme weather conditions, comprising liposomes and mRNA molecules with enhanced stability in high-temperature environments. Additionally, it includes a method for delivering RNA to trigger multiple immune pathways in a high-security facility, a composition for immunizing animals in disaster relief situations, a system for immunizing animals in remote, hard-to-reach areas, and a method for delivering RNA to trigger multiple immune pathways in a cold-chain storage facility. These specialized RNA delivery systems incorporate modified nucleotides, 5′ cap nucleosides, and sequences that encode specific immunogens to ensure effective immunization in diverse environments.

Novelty and Inventive Step

The new claims introduce novel adaptations of the original RNA delivery system, including modified nucleotides for enhanced stability, specialized sequences for specific immunogens, and tailored compositions for unique operational environments. These adaptations provide a non-obvious solution to the problem of limited efficacy and stability in diverse environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include RNA delivery systems for immunizing animals in other specialized environments, such as space exploration or high-altitude areas. Variations could also include different types of immunogens, modified liposomes, or alternative RNA molecules.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as biotechnology, pharmaceuticals, and veterinary medicine, particularly in areas with high demand for specialized immunization solutions, such as disaster relief, high-security facilities, and extreme weather environments.

Field of Art

Nucleic acid delivery systems for immunization, specifically non-viral RNA delivery technologies with a focus on liposomal formulations and modified RNA molecules for vaccine development

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with expertise in molecular biology, immunology, and pharmaceutical formulation, possessing knowledge of RNA modification techniques, liposomal delivery systems, and vaccine design strategies

Obviousness Rationale

A person having ordinary skill in the art would recognize that the published technical disclosure represents predictable variations of the source patent's core RNA delivery technology by applying known modification techniques to address specific environmental and operational challenges. The PTD's specialized delivery systems utilize well-established RNA modification strategies and liposomal formulation principles that are directly suggested by the source patent's teachings. These variations represent routine optimization of existing RNA delivery technologies through standard engineering approaches.

Obvious Combinations & Variations

Source Patent Element
Liposomal RNA composition with modified nucleotides
PTD Variation
Enhanced stability RNA delivery for extreme weather conditions
Obviousness Reasoning
A PHOSITA would find it obvious to modify nucleotide compositions to improve environmental stability using known chemical modification techniques, as this represents a predictable solution to temperature-related RNA degradation
Source Patent Element
mRNA molecules with 5' cap nucleoside
PTD Variation
Specialized RNA delivery for high-security and remote environments
Obviousness Reasoning
Adapting existing RNA delivery systems to specific operational contexts is a routine design choice that would be obvious to a skilled practitioner seeking to extend vaccine technologies to novel application scenarios
Source Patent Element
Influenza virus immunogen encoding sequences
PTD Variation
Multi-valent and specialized immunogen sequences for diverse scenarios
Obviousness Reasoning
Modifying immunogen sequences to target specific viral strains or create multi-valent vaccines represents a standard approach in vaccine development that would be obvious to a person skilled in the art
Source Patent Element
Non-viral RNA delivery composition
PTD Variation
Portable RNA delivery devices for remote immunization
Obviousness Reasoning
Developing portable delivery mechanisms for existing RNA vaccine technologies is a predictable engineering solution that would be obvious to a PHOSITA seeking to expand vaccine accessibility
Source Patent Element
RNA molecules with modified nucleotides
PTD Variation
Cold-chain storage optimized RNA delivery systems
Obviousness Reasoning
Optimizing RNA stability through nucleotide modifications for different storage conditions represents a known and predictable approach in pharmaceutical formulation technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857562, the present published technical disclosure demonstrates that the variations in RNA delivery systems for specialized immunization needs would have been obvious to a person having ordinary skill in the art at the time of invention. The disclosed adaptations represent routine optimization of known RNA delivery technologies through predictable modifications of nucleotide compositions, delivery mechanisms, and immunogen sequences, thereby rendering potential patent claims obvious and anticipating future attempts to claim such straightforward technological extensions.

Original Patent Information

Patent NumberUS 11,857,562
TitleDelivery of RNA to trigger multiple immune pathways
Assignee(s)GlaxoSmith Kline Biologicals S.A.